Capricor receives FDA RMAT Designation for Duchenne Muscular Dystrophy Therapy
Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational cell therapy for the treatment of Duchenne muscular…
Read More...
Read More...
